News in immunotherapy for metastatic melanoma: prolgolimab in clinical practice (authors' experience)

News in immunotherapy for metastatic melanoma: prolgolimab in clinical practice (authors' experience)

The incidence of skin melanoma is growing globally and in Russia. Also, the proportion of patients with advanced skin melanoma prevails. Introduction into clinical practice of a novel group of immunological drugs (anti-CTLA4 and anti-PD-1) for metastatic melanoma increased the time to disease progre...

Full description

Bibliographic Details
Main Authors:	Liana V. Oganesyan, Nikolay S. Karnaukhov, Polina S. Feoktistova
Format:	Article
Language:	Russian
Published:	IP Habib O.N. 2023-12-01
Series:	Современная онкология
Subjects:	metastatic melanoma immunotherapy immune checkpoint inhibitors ctla-4 pd-1 ipilimumab nivolumab prolgolimab pembrolizumab
Online Access:	https://modernonco.orscience.ru/1815-1434/article/viewFile/608171/pdf

Similar Items

Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study
by: Kristina V. Orlova, et al.
Published: (2023-02-01)

Cutaneous Melanoma versus Vulvovaginal Melanoma—Risk Factors, Pathogenesis and Comparison of Immunotherapy Efficacy
by: Anna Lorenz, et al.
Published: (2022-10-01)

Thyroid disorders induced by immune checkpoint inhibitors therapy of malignant tumors
by: Anastasiya A. Glibka, et al.
Published: (2022-10-01)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
by: Muhammad Zubair Afzal, et al.
Published: (2018-07-01)

Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis
by: Karlsson AK, et al.
Published: (2017-08-01)

Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
by: Ernesto Rossi, et al.
Published: (2019-07-01)

Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy
by: Pawel Teterycz, et al.
Published: (2020-10-01)

Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
by: Gabriele Madonna, et al.
Published: (2021-08-01)

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma
by: Taylor E. Woo, et al.
Published: (2023-09-01)

Fractal and Multifractal Analysis of PET-CT Images for Therapy Assessment of Metastatic Melanoma Patients under PD-1 Inhibitors: A Feasibility Study
by: Anastasia Kosmou, et al.
Published: (2021-10-01)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
by: Samuel Rosner, et al.
Published: (2018-03-01)

IPILIMUMAB IN THERAPY OF METASTATIC MELANOMA
by: I. V. SAMOILENKO, et al.
Published: (2016-12-01)

Associated Myocarditis: A Predictive Factor for Response?
by: Walid Shalata, et al.
Published: (2020-05-01)

Immunotherapy and Cannabis: A Harmful Drug Interaction or Reefer Madness?
by: Brian J. Piper, et al.
Published: (2024-03-01)

Outcome of Elective Checkpoint Inhibitor Discontinuation in Patients with Metastatic Melanoma Who Achieved a Complete Remission: Real-World Data
by: Leanne Perez, et al.
Published: (2022-05-01)

Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results
by: Thilo Gambichler, et al.
Published: (2019-12-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
by: Justin C. Moser, et al.
Published: (2019-12-01)

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
by: Sarabjot Pabla, et al.
Published: (2019-02-01)

Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
by: Sadanori Furudate, et al.
Published: (2016-10-01)

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
by: Wolfram Samlowski, et al.
Published: (2021-11-01)

Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials
by: Melissa Bersanelli, et al.
Published: (2022-05-01)

Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma
by: Trevor E. Angell, et al.
Published: (2018-03-01)

Anti-PD-1 Therapy in Advanced Pediatric Malignancies in Nationwide Study: Good Outcome in Skin Melanoma and Hodgkin Lymphoma
by: Agata Marjańska, et al.
Published: (2024-02-01)

Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
by: Marieke J. Krimphove, et al.
Published: (2019-11-01)

Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature
by: Johann Stuby, et al.
Published: (2020-11-01)

Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
by: Selina K. Wong, et al.
Published: (2021-11-01)

Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy
by: Matthew D Biniakewitz, et al.
Published: (2021-01-01)

Immunotherapy in Small Cell Lung Cancer
by: Giovanna Esposito, et al.
Published: (2020-09-01)

Stage 4 Cytokine Release Syndrome Caused by the First Dose of Nivolumab and Ipilimumab Combination Therapy in a Patient with Metastatic Melanoma Successfully Treated with Methylprednisolone, Tocilizumab, and Etanercept
by: Sasmith R. Menakuru, et al.
Published: (2022-06-01)

Melanoma en pacientes receptores de un trasplante de órgano sólido
by: C. González-Cruz, et al.
Published: (2021-03-01)

Lack of Influence of Non-Overlapping Mutations in <i>BRAF</i>, <i>NRAS</i>, or <i>NF1</i> on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma
by: Alyssa Panning, et al.
Published: (2023-07-01)

Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors
by: Kremena Petrova Trichkova, et al.
Published: (2024-01-01)

Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study
by: Igor V. Samoylenko, et al.
Published: (2023-12-01)

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA
by: I. V. SAMOILENKO, et al.
Published: (2017-06-01)

Bilateral anterior uveitis after immunotherapy for malignant melanoma
by: Chia-Jui Chang, et al.
Published: (2018-01-01)

Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade
by: Thilo Gambichler, et al.
Published: (2017-05-01)

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
by: Markus V. Heppt, et al.
Published: (2019-11-01)

Limbic encephalitis in metastatic malignant melanoma patient induced by PD-1 checkpoint inhibitor pembrolizumab
by: Rozala Arko, et al.
Published: (2022-07-01)

The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma
by: Shantanu Banerji, et al.
Published: (2021-11-01)

Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab
by: S. Morteza Seyed Jafari, et al.
Published: (2020-10-01)